|
|
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD |
| 3U01NS101944-05S1 |
|
NINDS |
2022 |
|
|
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD |
| 3U01NS101944-05S1 |
|
NINDS |
2022 |
|
|
Supplementary funding for U01NS104326 Clinical Trial Readiness for SCA1 and SCA3 (“READISCA”) |
| 3U01NS104326-05S1 |
|
NINDS |
2022 |
|
|
Supplementary funding for U01NS104326 Clinical Trial Readiness for SCA1 and SCA3 (“READISCA”) |
| 3U01NS104326-05S1 |
|
NINDS |
2022 |
|
|
Development of a nanoparticle-based gene editing technology for neurological applications |
| 3UH3NS115599-04S1 |
|
NINDS |
2022 |
|
|
Development of a nanoparticle-based gene editing technology for neurological applications |
| 3UH3NS115599-04S1 |
|
NINDS |
2022 |
|
|
Translating Genetic Risk Factors to Therapies: From Big Data to Druggable Targets |
| 4K00NS120365-02 |
|
NINDS |
2022 |
|
|
Noninvasive, wireless thermal sensors for the quantitative monitoring of ventricular shunt function in patients with hydrocephalus |
| 4U44NS121555-02 |
|
NINDS |
2022 |
|
|
Noninvasive, wireless thermal sensors for the quantitative monitoring of ventricular shunt function in patients with hydrocephalus |
| 4U44NS121555-02 |
|
NINDS |
2022 |
|
|
Development of a Nanoparticle-Based Gene Editing Technology for Neurological Applications |
| 4UH3NS115599-04 |
|
NINDS |
2022 |